Where Can In Vitro Diagnostics Flourish?

MedTech Outlook | Monday, August 31, 2020

In-vitro diagnostics testing is a cost-effective method for the healthcare system and contributes to much clinical practice.

Fremont, CA: In-vitro diagnostics (IVD) can detect diseases or other conditions and can be utilized to monitor a person's overall health and help cure, treat, and prevent diseases. It can also be used in precision medicine to identify patients who benefit from specific treatments or therapies. These in the Vitro diagnostics can consist of next-generation sequencing tests that scan a person's DAN to detect genomic variations. In-vitro diagnostics (IVD) is a booming market, which is one reason for many continues to have to track the market using market research aids. 

Cost-effectiveness

The cost-effectiveness of IVDs should be easy to establish. The most severe healthcare decisions are made based on a test while costing little to the healthcare system. For some time, this has been stated as an educational conjecture; a recent study of U.S and German physicians offer proof. The study found that 66 percent of clinical decisions were made based on a diagnostic test, while those tests' costs were just 2.3 percent of healthcare expenditure.

Anti-microbial resistance

Anti-microbial resistance continues to be a part where IVD shines; there is a growing realization that blind prescribing of antibiotics can be reduced with faster and more targeted testing. There are various ways to handle this — syndromic pathogen testing, rapid respiratory point of care to avoid antibiotic prescriptions for viral conditions, and faster blood culture with fewer operator steps.  

Opiods

Despite significant attention and much action, the opioid crisis continues to plague the United States and other countries. In 2018, total overdose numbers remained over 70,000 per CDC statistics, pointing out that the problem is still severe. However, if the lab is involved earlier, doctors won not make many prescribing or diagnostic mistakes. 

Global Blood Banking

According to WHO statistics, 78 countries collect over 90 percent of their blood supply from voluntary unpaid blood donors, and 56 of those countries do so for all of their blood supply. That progress comes with a threat. With the increased globalization of tropical diseases, blood systems in the developed world are under siege. 

First, it was hepatitis B and C, then HIV, Chagas, BSE, and West Nile and more recently emerging threats Zika Virus, Plasmodium species (malaria), Dengue virus, chikungunya, and yellow fever. Improved immunoassay screens, specific pathogen testing, and NAT molecular blood testing can assist, and these will factor into some component of the growth in this market.

See also: Top CMOs